Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
CagriSema CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes.
The most common adverse events are gastrointestinal-related, such as nausea, vomiting, constipation, stomach pain, and diarrhea
Working well
The best way is to gently swirl the vial in slow circles or roll it between your palms
We'll match your condition to the right protocol, supply pharmaceutical-grade peptide and sterile injection kits, and walk you through every step from first injection to follow-up
